Skip to main content

Table 3 Tumor response assessment and correlation to  KRAS  mutational status

From: Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group

All patients

All

WT

Codon 12 mutation

Codon 13 mutation

p-value

No. of patients%

201

128

58

15

 

100

63.6

28.9

7.5

ORR%

55

63

49

23

0.008

95% CI

(49–61)

(54–71)

(37–62)

(8–51)

(Chi-Square)

DCR%

85

88

81

77

0.29

95% CI

(80–90)

(80–92)

(68–89)

(49–93)

(Chi-Square)

  1. All patients. Percentages based on non-missing data, p-values for WT vs Codon 12 mutations vs codon 13 mutations; WT wild type; ORR overall response rate, DCR disease control rate.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us